Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC29A1 | Q99808 | 6/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 6/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 6/20 | 0.40 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | PGK1 | P00558 | 1/20 | 0.38 |
| ▸ | PGK2 | P07205 | 1/20 | 0.38 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.37 |
| ▸ | PDE2A | O00408 | 1/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.37 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.37 |
| ▸ | HINT1 | P49773 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16374032 | 0.87 | SLC29A1 (0.37) | SLC29A1ADORA3ADORA1ADORA2BADORA2A | |
| SCHEMBL16373936 | 0.87 | SLC29A1 (0.37) | SLC29A1ADORA3ADORA1ADORA2BADORA2A | |
| SCHEMBL15255196 | 0.86 | SLC29A1 (0.41) | SLC29A1ADORA3ADORA1ADORA2BADORA2A | |
| SCHEMBL20194538 | 0.83 | P2RY1 (0.43) | — | |
| SCHEMBL15070700 | 0.83 | SLC29A1 (0.39) | SLC29A1ADORA3ADORA1ADORA2BADORA2A | |
| SCHEMBL16573481 | 0.81 | HSP90B1 (0.48) | SLC29A1ADORA3ADORA1ADORA2BADORA2A | |
| SCHEMBL16214124 | 0.81 | SLC29A1 (0.38) | SLC29A1ADORA3ADORA1ADORA2BADORA2A | |
| SCHEMBL20628809 | 0.78 | NT5E (0.37) | SLC29A1HSP90B1HINT1 | |
| SCHEMBL19766096 | 0.78 | CYP2C19 (0.42) | SLC29A1ADORA3ADORA1ADORA2BADORA2A | |
| SCHEMBL19766095 | 0.78 | CYP2C19 (0.42) | SLC29A1ADORA3ADORA1ADORA2BADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10307439-B2 | Substituted nucleosides, nucleotides and analogs thereof | ALIOS BIOPHARMA, INC. (US) | 2019-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10307439-B2 | Substituted nucleosides, nucleotides and analogs thereof | PNP, NT5C3B, TYMP | SLC29A1 14/4885ADORA3 83/4885ADORA1 109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.